{{Rsnum
|rsid=1339219
|Gene=ESRRG
|Chromosome=1
|position=216999050
|Orientation=plus
|GMAF=0.3802
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=ESRRG
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 25.9 | 42.9 | 31.2
| HCB | 8.8 | 32.8 | 58.4
| JPT | 4.4 | 42.5 | 53.1
| YRI | 18.4 | 51.7 | 29.9
| ASW | 19.3 | 43.9 | 36.8
| CHB | 8.8 | 32.8 | 58.4
| CHD | 3.7 | 36.7 | 59.6
| GIH | 19.8 | 47.5 | 32.7
| LWK | 14.5 | 50.9 | 34.5
| MEX | 10.5 | 43.9 | 45.6
| MKK | 16.2 | 44.2 | 39.6
| TSI | 37.3 | 34.3 | 28.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1339219
|Name_s=
|Gene_s=ESRRG
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.45, combined P value= 2.78E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470224
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1339219
|overall_frequency_n=58
|overall_frequency_d=128
|overall_frequency=0.453125
|n_genomes=40
|n_genomes_annotated=0
|n_haplomes=52
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}